Marshall Wace’s scPharmaceuticals SCPH Stock Holding History

Marshall Wace’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26,880	Closed	-$152K	–	3426
2025 Q3	$152K	Buy	+26,880	New	+$138K	﹤0.01%	2604
2025 Q2	–	Sell	-73,210	Closed	-$193K	–	3110
2025 Q1	$193K	Buy	+73,210	New	+$238K	﹤0.01%	2415
2024 Q4	–	Sell	-23,646	Closed	-$108K	–	2956
2024 Q3	$108K	Buy	+23,646	New	+$114K	﹤0.01%	2366
2024 Q1	–	Sell	-34,369	Closed	-$215K	–	2771
2023 Q4	$215K	Buy	+34,369	New	+$197K	﹤0.01%	1963
2023 Q2	–	Sell	-52,380	Closed	-$475K	–	2921
2023 Q1	$475K	Sell	52,380 -60,322	-54%	-$442K	﹤0.01%	2124
2022 Q4	$808K	Buy	+112,702	New	+$689K	﹤0.01%	2174

Marshall Wace's SCPH Position: Q4 2025 in Review

Marshall Wace sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 26,880 shares — an estimated $152K sold.

Marshall Wace first reported a position in SCPH in Q4 2022 and held it in 6 quarters. The position peaked at $808K in Q4 2022. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

Marshall Wace reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 26,880 scPharmaceuticals shares in Q4 2025, an estimated $152K.
Marshall Wace first reported a position in scPharmaceuticals in Q4 2022 and held it in 6 quarters.
Marshall Wace's scPharmaceuticals position peaked at $808K in Q4 2022.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.